Affiliation:
1. Bioanalytical Chemistry, Drug Safety Sciences, Johnson & Johnson Pharmaceutical Research & Development, 1000 Route 202 South, Raritan, NJ 08869, USA
Abstract
Increasing emphasis has been placed on quantitative characterization of drug metabolites during drug discovery and development. Due to the more polar nature of drug metabolites, quantitative analysis using traditional reversed-phase liquid chromatography tandem mass spectrometry (RPLC–MS/MS) can be quite challenging. As an alternative chromatographic mode, hydrophilic interaction chromatography (HILIC) offers unique advantages for analysis of polar metabolites, providing better retention/separation, higher sensitivity, higher efficiency and potential for ultra-fast analysis to improve throughput. In this article, selected case studies from the authors’ own laboratory, and examples from current literature, will be discussed to demonstrate some practical considerations for method development of HILIC–MS/MS assays. The effectiveness of using HILIC–MS/MS for mitigating analytical challenges associated with quantitation of polar metabolites, including phase I and II metabolites of drugs, as well as endogenous metabolites, will be exhibited.
Subject
Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry
Reference51 articles.
1. Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment
2. Which Human Metabolites Have We MIST? Retrospective Analysis, Practical Aspects, and Perspectives For Metabolite Identification and Quantification in Pharmaceutical Development
3. US FDA. Guidance for Industry: Safety Testing of Drug Metabolites.Guidance for Industry: Safety Testing of Drug Metabolites. (2008).
4. ICH. CPMP/ICH/286/95 ICH Topic M3 (R2) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.CPMP/ICH/286/95 ICH Topic M3 (R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. (2009).
5. Potential bias and mitigations when using stable isotope labeled parent drug as internal standard for LC–MS/MS quantitation of metabolites
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献